GO:0005114 type II transforming growth factor beta receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005114 describes the molecular function of binding to a type II transforming growth factor beta receptor (TGF-beta RII), a core event in TGF-beta signal transduction [1, 5].
• Ligand binding induces type II receptor dimerization, a critical step for receptor activation and downstream signaling.
• The type II receptor is a serine/threonine kinase that, upon ligand binding, phosphorylates and activates type I receptors, propagating signals to SMAD proteins.
• Altered expression or function of TGF-beta RII is linked to human diseases including retinoblastoma and liver fibrosis [2, 3].
• Binding proteoglycans and albumin can modulate TGF-beta receptor interactions, affecting cellular responses [7, 8].
• Studying GO:0005114 requires methods such as single-molecule imaging, receptor binding assays, and CRISPR-based gene editing to dissect mechanism and disease relevance.
Description
Type II transforming growth factor beta receptor binding (GO:0005114) is a molecular function that mediates the initial interaction between TGF-beta ligands and the type II TGF-beta receptor (TGF-beta RII) [1, 5]. This binding event is the first step in TGF-beta signaling, a pathway that controls cell proliferation, differentiation, migration, and apoptosis [1, 6]. The type II receptor is a transmembrane serine/threonine kinase that, upon ligand binding, forms dimers and phosphorylates type I receptors, thereby activating SMAD-dependent and SMAD-independent signaling cascades [4, 6]. Researchers study GO:0005114 to understand how cells sense and respond to TGF-beta, and how dysregulation of this interaction contributes to diseases such as cancer, fibrosis, and developmental disorders [2, 3]. The binding specificity and affinity are influenced by accessory proteins and proteoglycans, adding layers of regulation [7, 8]. This article provides a comprehensive overview of the biological process, cellular components, and molecular mechanisms associated with type II TGF-beta receptor binding, highlighting key genes, disease connections, and experimental approaches including CRISPR-based models.
type II transforming growth factor beta receptor binding At A Glance
| GO ID | GO:0005114 |
|---|---|
| GO term | type II transforming growth factor beta receptor binding |
| Ontology | molecular_function |
| Synonym | punt binding; punt ligand; TGF-beta type II binding; transforming growth factor beta ligand binding to type II receptor; transforming growth factor beta receptor type II binding; type II TGF-beta binding |
| Major function | Binding to type II TGF-beta receptor, initiating receptor dimerization and downstream signaling [1, 4] |
| Related receptor | TGF-beta RII (TGFBR2), a serine/threonine kinase receptor |
| Downstream effect | Activation of type I receptors and SMAD-mediated transcription |
| Disease relevance | Implicated in retinoblastoma, liver fibrosis, and other TGF-beta-related pathologies [2, 3] |
What Is GO:0005114?
GO:0005114 is defined as the molecular function of binding to a type II transforming growth factor beta receptor. It encompasses the physical interaction between a ligand (typically a TGF-beta family member) and the type II receptor, which is a key event in initiating TGF-beta signaling [1, 5].
Why Is type II transforming growth factor beta receptor binding Important in Cell Biology?
Type II TGF-beta receptor binding is a fundamental molecular event that governs the entire TGF-beta signaling pathway, which is essential for normal development and tissue homeostasis [1, 6]. Dysregulation of this binding interaction can lead to uncontrolled cell growth, fibrosis, and immune evasion, making it a critical target for therapeutic intervention and a focus of cancer and fibrosis research [2, 3].
• Initiates TGF-beta signaling, a pathway controlling cell growth, differentiation, and apoptosis [1, 6].
• Type II receptor dimerization upon ligand binding is a key activation step.
• Mutations or loss of TGF-beta RII expression are associated with retinoblastoma.
• Targeting TGF-beta RII binding can ameliorate liver fibrosis.
• Binding proteoglycans modulate ligand-receptor interactions and signaling outcomes.
• Albumin can upregulate type II receptor expression in proximal tubular cells, linking to kidney disease.
• Understanding binding specificity aids in designing receptor antagonists or agonists.
• CRISPR screens can identify genes regulating this binding event.
• Single-molecule imaging reveals dynamic receptor dimerization.
• The function is conserved across species, with Drosophila punt as a homolog.
Mechanism, Genes and Research Methods
Ligand Recognition and Binding
In simple terms: TGF-beta ligands grab onto the type II receptor on the cell surface.
TGF-beta ligands, such as TGF-beta1, bind with high affinity to the extracellular domain of the type II receptor (TGF-beta RII) [1, 5]. This binding is the first step in signal transduction and is highly specific, ensuring that only appropriate ligands activate the pathway. The interaction involves conserved cysteine residues and hydrophobic patches on both ligand and receptor.
Receptor Dimerization and Activation
In simple terms: Once bound, two type II receptors pair up and become active enzymes.
Ligand binding induces dimerization of type II receptors, a process visualized by single-molecule imaging. Dimerization brings the intracellular kinase domains into proximity, enabling autophosphorylation and activation. The activated type II receptor then phosphorylates type I receptors, which propagate the signal.
Type I Receptor Recruitment and Phosphorylation
In simple terms: The active type II receptor turns on type I receptors by adding phosphate groups.
The type II receptor kinase phosphorylates specific serine and threonine residues in the GS domain of type I receptors (e.g., TGF-beta RI/ALK5). This phosphorylation activates the type I receptor kinase, which subsequently phosphorylates SMAD2/3, leading to complex formation with SMAD4 and nuclear translocation to regulate gene expression.
Modulation by Accessory Proteins
In simple terms: Other proteins can stick to TGF-beta or the receptor and change how well they bind.
Binding proteoglycans, such as betaglycan and decorin, can sequester TGF-beta or present it to the type II receptor, thereby modulating signaling. Albumin has been shown to upregulate type II receptor expression in proximal tubular cells, affecting TGF-beta responsiveness. These accessory molecules add layers of regulation to the binding event.
Key Genes Involved in GO:0005114 type II transforming growth factor beta receptor binding
The following genes and proteins are central to type II TGF-beta receptor binding and its downstream effects.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TGFBR2 | Encodes type II TGF-beta receptor; binds TGF-beta ligands | Mutations linked to cancer and fibrosis; target for CRISPR KO [2, 3] |
| TGFB1 | Major ligand that binds TGFBR2 | Key isoform in fibrosis and cancer; used in binding assays |
| TGFBR1 | Type I receptor phosphorylated by TGFBR2 | Mediates downstream SMAD activation |
| SMAD2 | Signal transducer phosphorylated by TGFBR1 | Readout of pathway activation |
| SMAD3 | Signal transducer phosphorylated by TGFBR1 | Readout of pathway activation |
| SMAD4 | Co-SMAD forming complexes with SMAD2/3 | Central to transcriptional regulation |
| ACVR2A | Related type II receptor for activin | Potential cross-talk with TGF-beta signaling |
| ACVR2B | Related type II receptor for activin | Potential cross-talk |
| BMPR2 | Type II receptor for BMPs | Shares homology with TGFBR2 |
| ENG | Endoglin, accessory protein for TGF-beta receptors | Modulates binding and signaling |
| DCN | Decorin, proteoglycan that binds TGF-beta | Regulates ligand availability |
| LTBP1 | Latent TGF-beta binding protein | Controls TGF-beta activation and presentation |
| PUNT | Drosophila homolog of TGFBR2 | Genetic studies of receptor function |
| TGFBR3 | Betaglycan, co-receptor for TGF-beta | Enhances ligand binding to TGFBR2 |
| FKBP1A | Immunophilin that binds TGFBR1 | Regulates receptor stability |
| STRAP | Serine-threonine kinase receptor associated protein | Modulates TGF-beta signaling |
| SMAD7 | Inhibitory SMAD | Negative feedback regulator |
How Is type II transforming growth factor beta receptor binding Regulated?
Type II TGF-beta receptor binding is regulated at multiple levels. Receptor expression can be upregulated by factors such as albumin in proximal tubular cells. Accessory proteins like betaglycan and decorin modulate ligand presentation and binding affinity. Intracellularly, inhibitory SMAD7 provides negative feedback by recruiting phosphatases to the receptor complex. Additionally, receptor trafficking and degradation control the availability of TGFBR2 at the cell surface.
type II transforming growth factor beta receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TGFBR2 | Retinoblastoma | TGFBR2 knockout in retinoblastoma cell lines |
| TGFBR2 | Liver fibrosis | TGFBR2 overexpression or KO in hepatic stellate cells |
| TGFBR2 | Kidney fibrosis | TGFBR2 KO in proximal tubular cells |
| TGFB1 | Fibrosis and cancer | TGFB1 point mutations to alter binding affinity |
| ENG | Hereditary hemorrhagic telangiectasia | ENG knockout endothelial cells |
Cancer: Retinoblastoma
Lack of TGF-beta type II receptor expression has been observed in human retinoblastoma cells, suggesting that loss of this binding function contributes to tumorigenesis by evading TGF-beta growth inhibition.
Liver Fibrosis
Dihydroergotamine ameliorates liver fibrosis by targeting TGF-beta type II receptor, indicating that modulating the binding interaction can reduce fibrotic progression.
Kidney Disease
Albumin upregulates type II TGF-beta receptor in cultured proximal tubular cells, linking altered receptor levels to kidney injury and fibrosis.
From type II transforming growth factor beta receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does TGFBR2 loss affect ligand binding? | TGFBR2 knockout cell line |
| How do point mutations in TGFBR2 alter binding affinity? | TGFBR2 point-mutation knock-in |
| Can we tag TGFBR2 to track its localization? | Tagged TGFBR2 knock-in (e.g., GFP) |
| What is the effect of TGFBR2 overexpression? | TGFBR2 overexpression stable pool |
| Which genes regulate TGFBR2 binding? | CRISPR library screening |
| How does TGF-beta ligand binding change transcriptome? | RNA-seq after ligand stimulation |
How to Study the type II transforming growth factor beta receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Single-molecule imaging | Receptor dimerization dynamics | Visualizing binding-induced activation |
| Surface plasmon resonance | Binding affinity (KD) | Quantifying ligand-receptor interactions |
| Co-immunoprecipitation | Protein-protein interactions | Identifying receptor complexes |
| CRISPR knockout | Gene function loss | Testing necessity of candidate genes |
| RNA-seq | Transcriptional changes | Downstream effects of binding |
| Western blot | Protein expression and phosphorylation | Validating receptor activation |
| Luciferase reporter assay | SMAD-dependent transcription | Measuring pathway activity |
Single-Molecule Imaging
Single-molecule imaging has been used to visualize TGF-beta-induced type II receptor dimerization in real time, providing direct evidence of binding and activation steps.
Receptor Binding Assays
Radiolabeled or fluorescently labeled TGF-beta ligands can be used to measure binding affinity and specificity to type II receptors in vitro [1, 5].
CRISPR-Based Genetic Screens
Genome-wide CRISPR knockout or activation screens can identify genes that modulate type II TGF-beta receptor binding and downstream signaling.
Proteomics and Co-Immunoprecipitation
Co-immunoprecipitation followed by mass spectrometry can identify proteins that interact with the type II receptor upon ligand binding, revealing accessory factors.
How CRISPR Can Be Used to Study GO:0005114 type II transforming growth factor beta receptor binding
Knockout
CRISPR knockout of TGFBR2 or other genes can abolish type II receptor binding, allowing researchers to test its requirement for TGF-beta signaling and disease phenotypes [2, 6].
Point Mutation
Introducing point mutations in the ligand-binding domain of TGFBR2 can dissect residues critical for binding affinity and specificity, as well as disease-associated variants.
Knock-in
Knock-in of tagged TGFBR2 (e.g., GFP or HA) enables live-cell imaging and proteomic analysis of the receptor without altering its endogenous regulation.
Overexpression
Overexpression of TGFBR2 or its ligands can amplify signaling and is useful for studying gain-of-function effects in fibrosis and cancer models [3, 7].
How EDITGENE Supports type II transforming growth factor beta receptor binding Research
Researchers studying type II transforming growth factor beta receptor binding-related genes often need to determine whether a candidate gene is causally involved in the binding event or downstream signaling. EDITGENE provides a comprehensive suite of CRISPR services to generate precisely engineered cell models, enabling rigorous functional validation.
Contact EDITGENE today to design your custom CRISPR model for type II transforming growth factor beta receptor binding research.
Frequently Asked Questions About type II transforming growth factor beta receptor binding
What is type II transforming growth factor beta receptor binding?
It is the molecular function (GO:0005114) of a ligand binding to the type II TGF-beta receptor, initiating TGF-beta signaling [1, 5].
What genes are involved in type II TGF-beta receptor binding?
Key genes include TGFBR2 (the receptor), TGFB1 (ligand), and accessory proteins like ENG and DCN [1, 8].
How does type II receptor binding lead to signaling?
Binding induces receptor dimerization and phosphorylation of type I receptors, which activate SMAD proteins [4, 6].
What diseases are associated with defects in this binding?
Retinoblastoma, liver fibrosis, and kidney fibrosis have been linked to altered type II receptor expression or function [2, 3, 7].
What methods are used to study type II TGF-beta receptor binding?
Single-molecule imaging, surface plasmon resonance, co-immunoprecipitation, and CRISPR screens are commonly used [4, 8].
Can CRISPR be used to study this binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models allow precise dissection of the binding event [2, 6].
What is the role of TGFBR2 in cancer?
Loss of TGFBR2 expression can contribute to cancer by evading TGF-beta growth inhibition, as seen in retinoblastoma.
How is type II receptor binding regulated?
It is regulated by receptor expression levels, accessory proteins like betaglycan, and inhibitory SMAD7 [6, 7, 8].
What is the Drosophila homolog of TGFBR2?
The Drosophila homolog is punt, which is involved in TGF-beta-like signaling.
Why is type II TGF-beta receptor binding important for drug discovery?
It is a critical node in fibrosis and cancer, making it a target for therapeutic intervention.
Conclusion
Type II transforming growth factor beta receptor binding (GO:0005114) is a pivotal molecular function that initiates TGF-beta signaling, influencing diverse cellular processes and disease states. Understanding its mechanism, regulation, and disease relevance is essential for developing targeted therapies. CRISPR-based models and advanced imaging techniques continue to unravel the complexities of this binding event, offering new avenues for research and therapeutic intervention.
References
- 1. Massagué J et al.. 1992. TGF-beta receptors.. Mol Reprod Dev 32(2):99-104 PMID: 1322148
- 2. Horie K et al.. 1998. Lack of transforming growth factor-beta type II receptor expression in human retinoblastoma cells.. J Cell Physiol 175(3):305-13 PMID: 9572475
- 3. Zheng KX et al.. 2023. Dihydroergotamine ameliorates liver fibrosis by targeting transforming growth factor β type II receptor.. World J Gastroenterol 29(20):3103-3118 PMID: 37346154
- 4. Zhang W et al.. 2009. Single-molecule imaging reveals transforming growth factor-beta-induced type II receptor dimerization.. Proc Natl Acad Sci U S A 106(37):15679-83 PMID: 19720988
- 5. Segarini PR. 1991. TGF-beta receptors.. Ciba Found Symp 157:29-40; discussion 41-50 PMID: 1649036
- 6. Bassing CH et al.. 1994. A transforming growth factor beta type I receptor that signals to activate gene expression.. Science 263(5143):87-9 PMID: 8272871
- 7. Wolf G et al.. 2004. Albumin up-regulates the type II transforming growth factor-beta receptor in cultured proximal tubular cells.. Kidney Int 66(5):1849-58 PMID: 15496155
- 8. Boyd FT et al.. 1990. Transforming growth factor-beta receptors and binding proteoglycans.. J Cell Sci Suppl 13:131-8 PMID: 1964683
